Sellas Life Sciences Group, Inc. (SLS) intrinsic value & 10-year financials
Sellas Life Sciences Group, Inc. (SLS) has a Graham intrinsic value of $10.01 per share. At $9.98 on Oct 17, 2026, the stock trades 0% below that value.
- Graham intrinsic value
- $10.01
- Share price (Oct 17, 2026)
- $9.98
- Price vs Graham value
- 0% below
- Market cap
- $1.1B
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -27.4%
- ROIC (10-yr avg)
- 630.0%
- Free cash flow (FY2025)
- —
SLS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$26.9M | -$0.25 | — | — | 1276.8% |
| FY2024 | — | -$30.9M | -$0.50 | — | — | 449.9% |
| FY2023 | $0 | -$37.3M | -$1.34 | — | — | 348.3% |
| FY2022 | $1.0M | -$41.3M | -$2.13 | — | -4195.0% | 693.4% |
| FY2021 | $7.6M | -$20.7M | -$1.34 | — | -332.8% | 723.4% |
| FY2020 | $1.9M | -$16.8M | -$1.05 | — | -893.8% | 440.6% |
| FY2019 | $0 | -$19.3M | — | — | — | 3128.1% |
| FY2018 | — | -$27.7M | — | — | — | -519.8% |
| FY2017 | $0 | -$23.8M | — | — | — | -122.2% |
| FY2016 | $0 | -$23.5M | — | -$44.9M | — | -118.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
SELLAS Life Sciences Group, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
SELLAS Life Sciences Group, Inc. has historically struggled to out-earn its cost of capital, averaging just -17.5% ROIC.
SELLAS Life Sciences Group, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, SELLAS Life Sciences Group, Inc. is modeled at -27.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $10.01 per share.